Article Synopsis
- Clinical trials are essential for assessing the safety and effectiveness of new medical treatments, but there is a noticeable lack of diversity among participants, particularly racial and ethnic minorities.
- Factors that influence the willingness of minority patients to join clinical trials include cultural barriers, lack of awareness, and mistrust in the medical system.
- This study explored these barriers through input from various stakeholders and developed potential solutions, using a behavior change framework to craft effective communication strategies to encourage greater participation among diverse populations.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Clinical trial results provide the critical evidence base for evaluating the safety and efficacy of new medicines and medical products. Efficacy and safety may differ among population subgroups depending on intrinsic/extrinsic factors, including sex, age, race, ethnicity, lifestyle, and genetic background. Racial and ethnic minorities continue to be underrepresented in cardiovascular and other clinical trials. Although barriers to diversity in trials are well recognized, sustainable solutions for overcoming them have proved elusive. We investigated barriers impacting minority patients' willingness to participate in trials and-based on literature review and evaluation, and input from key stakeholders, including minority patients, referring physicians, investigators who were minority-serving physicians, and trial coordinators-formulated potential solutions and tested them across stakeholder groups. We identified key themes from solutions that resonated with stakeholders using a transtheoretical model of behavior change and created a communications message map to support a multistakeholder approach for overcoming critical participant barriers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpcardiol.2018.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives.
J Cell Mol Med
September 2025
Department of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Dhaka, Bangladesh.
Ferroptosis, a controlled cell death influenced by iron-dependent lipid peroxidation, presents potential therapeutic targets for cancer treatment due to its unique molecular pathways and potential drug resistance. Natural compounds, such as polyphenols, flavonoids, terpenoids and alkaloids, can influence ferroptosis via important signalling pathways, such as Nrf2/Keap1, p53, and GPX4. These are promising for combinational therapy due to their ability to cause ferroptotic death in cancer cells, exhibit tumour-specific selectivity and reduce systemic toxicity.
View Article and Find Full Text PDFTreatment modifiers and predictors of risperidone response in dementia: An individual participant data meta-analysis of six randomized controlled trials.
Alzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.
Bio-ethical issues of research in Sub-Saharan Africa.
Monash Bioeth Rev
September 2025
Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana.
This paper examines bioethical considerations of research conducted in Sub-Saharan Africa (SSA), where a notable scarcity persists in literature addressing region-specific bioethical issues. Although bioethics-related activities have encountered challenges surpassing existing protocol safeguards, emerging evidence demonstrates growing recognition of integrated scientific and ethical principles within African medical research. Maintaining research continuity in resource-limited settings necessitates bridging critical gaps between informed consent procedures and participants' actual understanding.
View Article and Find Full Text PDFTargeting Tregs in T1DM: bridging heterogeneity, mechanisms, and clinical progress.
Trends Pharmacol Sci
September 2025
Department of Biosciences and Bioinformatics & Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China; Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manch
Regulatory T cells (Tregs) play a pivotal role in maintaining immune tolerance and sustaining immunological homeostasis. Emerging evidence indicates that Treg characteristics and functional alterations can significantly contribute to the pathogenesis of autoimmune diseases including type 1 diabetes mellitus (T1DM). Notably, recent studies have established a positive correlation between diminished numbers of Tregs and the onset of T1DM.
View Article and Find Full Text PDFASAS recommendations on reporting axial spondyloarthritis clinical trials.
Ann Rheum Dis
September 2025
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Objectives: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS).
Methods: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented.